Adrenergic uptake inhibitors - Pipeline Insight, 2022

“Adrenergic Uptake Inhibitors - Pipeline Insight, 2022” report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in Adrenergic Uptake Inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered
• Global coverage

Adrenergic Uptake Inhibitors Understanding

Adrenergic Uptake Inhibitors: Overview

Adrenergic drugs are a broad class of medications that bind to adrenergic receptors throughout the body. These receptors include: alpha-1, alpha-2, beta-1, beta-2, beta-3. Adrenergic drugs will bind directly to one or more of these receptors to induce various physiologic effects. This activity examines the pharmacology, various therapeutic effects, and adverse events that class members can exert, which covers a wide variety of clinical manifestations.

Function - The adrenergic receptors or adrenoceptors are a class of G protein-coupled receptors that are targets of many catecholamines like norepinephrine (noradrenaline) and epinephrine (adrenaline) produced by the body

Adrenergic Uptake Inhibitors - Adrenergic Uptake Inhibitors are drugs that block the transport of adrenergic transmitters into axon terminals or into storage vesicles within terminals. The tricyclic antidepressants and amphetamines are among the therapeutically important drugs that may act via inhibition of adrenergic transport. Many of these drugs also block transport of serotonin.

Adrenergic Uptake Inhibitors Emerging Drugs Chapters

This segment of the Adrenergic Uptake Inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Adrenergic Uptake Inhibitors Emerging Drugs
• Ampreloxetine: Theravance Biopharma

Ampreloxetine is an investigational, once-daily norepinephrine reuptake inhibitor (NRI) being developed for the treatment of patients with symptomatic neurogenic orthostatic hypotension (nOH). The compound has high affinity for binding to norepinephrine transporters. By blocking the action of these transporters, ampreloxetine causes an increase in extracellular concentrations of norepinephrine. Currently, it is in phase 3 of development stage.
• Edivoxetine: Eli Lilly and Company

Edivoxetine (LY-2216684) is an antidepressant produced by US drug major Eli Lilly. The drug acts as a selective norepinephrine reuptake inhibitor and as a treatment for attention-deficit hyperactivity disorder (ADHD). Currently, it is in phase II/III stage of development

Further product details are provided in the report……..

Adrenergic Uptake Inhibitors: Therapeutic Assessment

This segment of the report provides insights about the different Adrenergic Uptake Inhibitors drugs segregated based on following parameters that define the scope of the report, such as:
• Major Players working on Adrenergic Uptake Inhibitors

There are approx. 15+ key companies which are developing the Adrenergic Uptake Inhibitors. The companies which have their Adrenergic Uptake Inhibitors drug candidates in the most advanced stage, i.e. phase III include, Theravance Biopharma.
• Phases

DelveInsight’s report covers around 15+ products under different phases of clinical development like
• Late-stage products (Phase III and
• Mid-stage products (Phase II and
• Early-stage products (Phase I/II and Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Adrenergic Uptake Inhibitors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Infusion
• Intradermal
• Intramuscular
• Intranasal
• Intravaginal
• Oral
• Parenteral
• Subcutaneous
• Topical.
• Molecule Type

Products have been categorized under various Molecule types such as
• Vaccines
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Adrenergic Uptake Inhibitors: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Adrenergic Uptake Inhibitors therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Adrenergic Uptake Inhibitors drugs.

Report Highlights
• The companies and academics are working to assess challenges and seek opportunities that could influence Adrenergic Uptake Inhibitors R&D. The therapies under development are focused on novel approaches for Adrenergic Uptake Inhibitors.

Adrenergic Uptake Inhibitors Report Insights
• Adrenergic Uptake Inhibitors Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Adrenergic Uptake Inhibitors Report Assessment
• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Scenario and Emerging Therapies:
• How many companies are developing Adrenergic Uptake Inhibitors drugs?
• How many Adrenergic Uptake Inhibitors drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for Adrenergic Uptake Inhibitors?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Adrenergic Uptake Inhibitors therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Adrenergic Uptake Inhibitors and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players
• Theravance Biopharma
• Eli Lilly and Company
• NLS Pharmaceutics Ltd
• DOV Pharmaceutical
• Tonix Pharmaceuticals Holding Corp
• Taiho Pharmaceutical
• Luye Pharma
• AbbVie
• Otsuka Pharmaceutical
• Axsome Therapeutics
• Sumitomo Dainippon Pharma
• Torrent Pharmaceuticals
• NeuroSearch
• Otsuka America Pharmaceutical
• YooYoung Pharmaceuticals
• MultiCell Technologies
• Qrono
• Apnimed

Key Products
• Ampreloxetine
• Edivoxetine
• Nolazol
• Amitifadine
• D 473
• TAS 303
• Toludesvenlafaxine extended release
• Levomilnacipran
• Centanafadine
• Reboxetine
• Dasotraline
• Tapentadol intranasal
• NS 2359
• OPC 64005
• YYC301
• LAX-202
• Quetiapine
• AD109